Zoetis Inc. ZTS
71.05
0.78
1.11%
as of 25 Sep
- Market cap
- $29.2B
- P/E
- 11.7×
Follow ZTS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Zoetis Inc. (ZTS) Net income
Zoetis Inc.'s net income for fiscal 2025 was $2.7B, up 7.09% from $2.5B in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.6B. Over the past ten years it has ranged from $339.0M (fiscal 2015) to $2.7B (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 10 consecutive fiscal years. Zoetis Inc. ranks 3rd of 86 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Annual
| Period | Net income | Change |
|---|---|---|
| FY2025 | $2.7B | 7.09% |
| FY2024 | $2.5B | 6.67% |
| FY2023 | $2.3B | 10.85% |
| FY2022 | $2.1B | 3.79% |
| FY2021 | $2.0B | 24.33% |
| FY2020 | $1.6B | 9.07% |
| FY2019 | $1.5B | 5.34% |
| FY2018 | $1.4B | 65.20% |
| FY2017 | $862.0M | 5.25% |
| FY2016 | $819.0M | 141.59% |
Quarterly
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $691.0M | 14.98% |
| Mar 2026 | $601.0M | (0.33%) |
| Dec 2025 | $603.0M | (18.73%) |
| Sep 2025 | $742.0M | 2.20% |
| 42 more quarters | Free account |
Against its own ten years
Low $339.0M
High $2.7B
Ten-year median
$1.6B
Current reading's percentile
100
Net income against peers
| Company | Net income |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $3.1B |
| TAK Takeda Pharmaceutical Co. compare | $2.9B |
| ZTS Zoetis Inc. | $2.6B |
| UTHR United Therapeutics Corporation compare | $1.3B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $709.0M |
| NBIX Neurocrine Biosciences, Inc. compare | $705.5M |
| RDY Dr. Reddy's Laboratories Ltd compare | $334.0M |
| ELAN Elanco Animal Health Incorporated compare | −$199.0M |
| VTRS Viatris Inc. compare | −$410.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ZTS
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement